Memory B Cells Predict Relapse in Rituximab-Treated Myasthenia Gravis

Area of Science:

• Immunology
• Neurology
• Pharmacology

Background:

• Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions.
• Rituximab is an effective treatment for MG, but optimal dosing and relapse prediction remain unclear.
• Identifying biomarkers for predicting clinical relapse in MG patients treated with rituximab is crucial.

Purpose of the Study:

• To identify B cell subpopulations that predict clinical relapse in generalized myasthenia gravis patients treated with rituximab.
• To establish a monitoring strategy for rituximab administration in MG.

Main Methods:

• Prospective collection of clinical and biological data from 34 generalized myasthenia gravis patients over 3 years.
• Multiparameter flow cytometry to assess B cell subpopulations (CD19+, CD27+) in residual and non-residual disease conditions.
• Clinical assessment using the Osserman score to evaluate disease severity and predict relapse.

Main Results:

• Clinical relapse occurred in 41% of patients, with a mean delay of 386.8 days after maintenance therapy.
• Increased CD27+ cells at relapse showed predictive value (AUC=0.7654).
• Memory B cells (CD19+CD27+) at a threshold of 0.01% demonstrated high sensitivity (75.8%) and specificity (72.8%) for predicting relapse.

Conclusions:

• The percentage of memory B cells in peripheral blood can accurately predict clinical relapse in myasthenia gravis patients receiving rituximab.
• Monitoring memory B cells allows for tailored rituximab administration and potentially fewer infusions.
• This finding supports personalized treatment strategies for myasthenia gravis.